EuroBiotech—More Articles of Note

(NS Newsflash/CC BY 2.0)

> GlaxoSmithKline offloaded its gene therapy portfolio to Orchard Therapeutics. The deal sees GSK gain a 20% stake in the gene therapy specialist and secure a stream of milestones and royalties in return for its approved portfolio and investigational pipeline. Statement

> Kenneth Newman, M.D., has resigned as Verona Pharma CMO. Release

> Genfit’s phase 3 NASH trial hit an enrollment milestone. Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Nanobiotix signed up to work with MD Anderson Cancer Center on its oncology drug NBTXR3. Release 

> Pharnext raised €16 million ($20 million) in a private placement. Statement

> Argenx cleared the third preclinical milestone in its ARGX-112 collaboration with LEO Pharma. Release

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.